Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Nuplazid on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Nuplazid (pimavanserin) is an antipsychotic medicine approved by the FDA specifically for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP).
Nuplazid works differently from older antipsychotic medicines. It selectively targets serotonin 5-HT2A receptors, without significant activity at dopamine receptors — a mechanism thought to reduce psychotic symptoms in Parkinson's disease without worsening the motor symptoms that dopamine-blocking antipsychotics can cause.
Nuplazid is indicated only for hallucinations and delusions that are associated with Parkinson's disease psychosis. It is not approved for dementia-related psychosis generally, unless the hallucinations and delusions are specifically related to Parkinson's disease.
The recommended dose of Nuplazid is 34 mg taken orally once daily, as two 17 mg capsules or one 34 mg capsule, with no titration required.
Boxed Warning — Nuplazid: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Nuplazid is not approved for the treatment of patients with dementia-related psychosis unless the hallucinations and delusions are associated with Parkinson's disease psychosis.
Nuplazid can prolong the QT interval. It should be avoided in patients with a history of cardiac arrhythmias, as well as in combination with other medicines known to prolong the QT interval, and in patients with congenital long QT syndrome.
Patients should be monitored for worsening of psychotic symptoms, cardiac symptoms, or signs consistent with QT prolongation while on treatment.
Dose considerations may apply in patients with significant renal or hepatic impairment; a treating physician should assess these factors before starting treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Nuplazid is manufactured and marketed by Acadia Pharmaceuticals. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating neurologist confirming a diagnosis of Parkinson's disease psychosis. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for Parkinson's disease psychosis, Nuplazid is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Nuplazid directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Nuplazid should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Nuplazid through NPP's regulated import pathway, with neurology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support neurology care coordination and documentation for Nuplazid access.
Delhi's major hospitals assist patients with prescription support and documentation for Nuplazid.
Bangalore's specialist network offers access coordination for eligible Parkinson's disease patients seeking Nuplazid.
Chennai-based neurology specialists coordinate Nuplazid access alongside comprehensive Parkinson's care.
Hyderabad's care institutions support patients pursuing Nuplazid therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Nuplazid.
Pune-based specialists assist with prescription support and Nuplazid treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Nuplazid.
Kochi's specialist units assist patients with the documentation needed for Nuplazid access.
Chandigarh's care centers support Nuplazid treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Nuplazid access process.
Lucknow-based centers assist patients pursuing Nuplazid therapy.
Bhubaneswar's institutions support access to Nuplazid for eligible patients.
Guwahati's specialists help coordinate Nuplazid access for patients across the Northeast.
Patients in other cities across India can also access Nuplazid through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
